Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.27 BRL | +1.39% | +0.69% | -10.04% |
Mar. 07 | Transcript : Dexco S.A., Q4 2023 Earnings Call, Mar 07, 2024 | |
Mar. 07 | Dexco S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Forest & Wood Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.04% | 1.16B | A- | ||
+4.39% | 5.36B | B- | ||
+3.73% | 3.33B | B- | ||
+4.81% | 1.39B | A- | ||
+20.32% | 1.24B | - | ||
-7.86% | 749M | - | ||
-20.54% | 707M | B- | ||
+10.55% | 548M | C- | ||
-14.00% | 529M | - | ||
-26.25% | 465M | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXCO3 Stock
- Ratings Dexco S.A.